ProShares Trust II (SVXY) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

High Risk
Significant dilution risk
Last updated: May 08, 2026

Risk Assessment Details

Potential Dilution: 113.37% of current shares
Recent Dilution: 151.7% (2 years)
Historical Dilution Factor: significant recent dilution
Outstanding Shares
290M
Potential Supply
330M
Additional shares possible
Splits
None
Past 2 years

Summary

SVXY currently has 295M outstanding shares. with significant dilution risk as 334M authorized shares could dilute existing holders by 113.4%. The company has significantly diluted shareholders by 151.7% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 08, 2026

10-Q filing | 295.0M shares outstanding

290M 330M
Aug 08, 2025

10-Q filing | 147.2M shares outstanding

150M 420M
May 09, 2025

10-Q filing | 110.5M shares outstanding

110M 460M
Mar 18, 2025

S-3/A filing: This SEC filing relates to legal proceedings involving GS&Co. as an underwriter in several securities offerings, focusing on allegations of material misstatements and omissions in offering documents.

130M 430M
Mar 18, 2025

S-3/A filing: This is an S-3/A filing on 2025-03-18, discussing underwriting litigation related to securities offerings from SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc., with allegations of material misstatements and omissions in offering documents.

130M 430M
Mar 18, 2025

S-1/A filing: This is an S-1/A filing on 2025-03-18. It discusses underwriting litigation related to securities offerings, including those of SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc.

130M 430M
Feb 28, 2025

10-K filing | 132.4M shares outstanding

130M 370M
Feb 13, 2025

S-1 filing: This SEC filing discusses underwriting litigation related to securities offerings by GS&Co., including cases involving SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA.

170M 450M
Feb 13, 2025

S-3 filing: The filing discusses legal proceedings against GS&Co. related to alleged misstatements and omissions in offering documents for various securities offerings, including SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc.

170M 330M
Feb 13, 2025

S-3 filing: This SEC filing discusses underwriting litigation involving GS&Co. in connection with securities offerings, including SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc.

170M 450M
Nov 18, 2024

10-Q filing | 173.8M shares outstanding

170M 270M
Aug 08, 2024

10-Q filing | 147.1M shares outstanding

150M 300M
May 09, 2024

10-Q filing | 126.2M shares outstanding

130M 320M
Mar 07, 2024

POS AM filing: This document discusses underwriting litigation involving GS&Co. in connection with securities offerings, including SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc.

150M 300M
Feb 28, 2024

10-K filing | 145.1M shares outstanding

150M 300M
Nov 06, 2023

10-Q filing | 106.3M shares outstanding

110M 340M
Aug 08, 2023

10-Q filing | 108.6M shares outstanding

110M 330M
May 08, 2023

10-Q filing | 631.5M shares outstanding

630M 0
Mar 27, 2023

POS AM filing: This is a POS AM filing mentioning several securities class actions related to public offerings underwritten by GS&Co.

460M 0
Mar 27, 2023

POS AM filing: This document discusses underwriting litigation involving Goldman Sachs as underwriter in multiple securities offerings, including ViacomCBS, SunEdison, Valeant Pharmaceuticals, and Snap Inc.

460M 0
Mar 27, 2023

POS AM filing: This is a POS AM filing from 2023-03-27 discussing legal proceedings against GS&Co. in connection with various securities offerings.

460M 0
Feb 28, 2023

10-K filing | 461.9M shares outstanding

460M 0
Feb 14, 2023

POS AM filing: This is a POS AM filing that discusses various legal proceedings involving Goldman Sachs, including antitrust claims, securities class actions, and underwriting litigation related to ViacomCBS and SunEdison.

180M 260M
Feb 14, 2023

POS AM filing: This is a POS AM filing that discusses legal proceedings related to Currencies-Related Litigation, Archegos-Related Matter, Underwriting Litigation, and SunEdison, Inc.

180M 260M
Nov 08, 2022

10-Q filing | 183.9M shares outstanding

180M 320M
Sep 26, 2022

POS AM filing: This is a POS AM filing that discusses several legal proceedings in which Goldman Sachs is involved, including antitrust claims, securities class actions related to ViacomCBS and SunEdison, and other underwriting litigation.

260M 240M
Sep 09, 2022

POS AM filing: This is a POS AM filing that discusses various legal proceedings in which GS&Co. is involved, including class action lawsuits related to securities offerings and antitrust claims.

260M 240M
Aug 09, 2022

10-Q filing | 260.8M shares outstanding

260M 240M
Jun 24, 2022

POS AM filing: This is a POS AM filing that discusses underwriting litigation related to securities offerings by GS&Co.

220M 280M
Jun 24, 2022

POS AM filing: This document discusses underwriting litigation involving GS&Co. as a defendant in securities class actions related to public offerings of various companies, including ViacomCBS, SunEdison, Valeant Pharmaceuticals, and Snap Inc.

220M 280M
May 09, 2022

10-Q filing | 222.5M shares outstanding

220M 410M
Feb 25, 2022

10-K filing | 145.9M shares outstanding

150M 480M
Feb 15, 2022

S-3/A filing: The filing discusses litigation involving Goldman Sachs and GS&Co. related to several securities offerings, including SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc. The plaintiffs allege material misstatements and omissions in the offering documents.

170M 460M
Feb 15, 2022

S-3/A filing: This is an S-3/A filing made on 2022-02-15. The filing discusses underwriting litigation, specifically proceedings related to securities offerings where GS&Co. is named as a defendant.

170M 460M
Feb 15, 2022

S-1 filing: This SEC filing discusses underwriting litigation involving GS&Co. in connection with securities offerings of SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc.

170M 460M
Feb 15, 2022

S-3 filing: This SEC filing discusses legal proceedings involving Goldman Sachs and other defendants related to alleged misstatements and omissions in offering documents for securities offerings of SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc.

170M 460M
Feb 15, 2022

S-1/A filing: This document discusses underwriting litigation involving GS&Co. in connection with securities offerings, including SunEdison, Valeant Pharmaceuticals, Snap Inc., and Altice USA, Inc.

170M 460M
Feb 15, 2022

S-3 filing: This filing discusses legal proceedings involving Goldman Sachs related to securities offerings, including SunEdison, Valeant Pharmaceuticals International, and Snap Inc.

170M 460M
Nov 05, 2021

10-Q filing | 165.1M shares outstanding

170M 150M
Sep 15, 2021

S-3 filing: The filing discusses legal proceedings involving Goldman Sachs and GS&Co. as underwriters and initial purchasers in securities offerings of SunEdison, Valeant Pharmaceuticals, and Snap Inc., alleging material misstatements and omissions in offering documents and seeking damages.

100M 210M
Sep 15, 2021

S-1 filing: The filing discusses legal proceedings involving Goldman Sachs and its subsidiaries related to securities offerings and other matters.

100M 210M
Aug 06, 2021

10-Q filing | 102.7M shares outstanding

100M 90M
May 07, 2021

10-Q filing | 344.9M shares outstanding

340M 0
Mar 12, 2021

S-1/A filing: The filing discusses legal proceedings involving Goldman Sachs, including matters related to currency exchange manipulation, underwriting of securities offerings for SunEdison and Valeant Pharmaceuticals.

130M 62M
Feb 23, 2021

S-3/A filing: This is an S-3/A filing providing information on legal proceedings involving Goldman Sachs & Co. LLC, including litigation related to securities offerings such as the SunEdison, Inc. convertible preferred stock offering.

130M 62M
Feb 19, 2021

10-K filing | 130.4M shares outstanding

130M 62M
Feb 16, 2021

S-3 filing: This SEC filing discusses legal proceedings involving Goldman Sachs and its subsidiaries, including litigation related to currencies, underwriting activities (specifically SunEdison, Valeant Pharmaceuticals, and Snap Inc. offerings).

180M 13M
Nov 09, 2020

10-Q filing | 180.2M shares outstanding

180M 0
Aug 12, 2020

S-1 filing: This is an S-1 filing, but it primarily discusses futures contracts, forward contracts, margin requirements, and FCM agreements related to trading activities. There is no specific offering of securities described within the provided text.

150M 0
Aug 10, 2020

10-Q filing | 153.4M shares outstanding

150M 0
May 08, 2020

10-Q filing | 0.1M shares outstanding

50K 130M
Mar 30, 2020

S-1/A filing: The filing describes the plan of distribution for shares of the fund, including the role of authorized participants and the potential for statutory underwriters.

130M 0
Mar 25, 2020

S-1/A filing: The filing discusses the plan of distribution for shares of the Funds, including buying and selling shares through brokers, offerings to Authorized Participants, and the likelihood of becoming a statutory underwriter.

130M 0
Mar 06, 2020

S-1 filing: The filing is an S-1 for a fund that continuously offers shares in Creation Units to Authorized Participants. Authorized Participants may then offer these shares to the public at market price.

130M 0
Feb 28, 2020

10-K filing | 130.4M shares outstanding

130M 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime